Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 21 Neoplasms 6 Carcinoma, Hepatocellular 5 Stomach Neoplasms 4 Recurrence 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Cancer 4 Uveal Melanoma 3 Urinary Bladder Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Liver Neoplasms 3 Colonic Neoplasms 3 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Neoplasm Metastasis 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Hodgkin Disease 2 Hematologic Neoplasms 2 Glioma 2 Glioblastoma 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Carcinoma, Basal Cell 2 Brain Neoplasms 2

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × relatlimab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡